Recent research suggests that GLP-1 medications, including semaglutide (commercially known as Ozempic, Wegovy, and Rybelsus), may be associated with improved mental health outcomes in patients with diabetes and obesity. Conducted by researchers from institutions such as the University of Eastern Finland and Karolinska Institutet in Stockholm, the study analyzed data from nearly 100,000 individuals, with over 20,000 having used GLP-1 medications between 2009 and 2022.
The study found that individuals using GLP-1 medications experienced a significant reduction in psychiatric-related hospital visits and took less time off work due to mental health issues. Specifically, during periods of semaglutide use, there was a reported 42% decrease in the need for psychiatric care. Additionally, the risk of depression decreased by 44%, while anxiety disorders were reduced by 38%. There was also a noted decrease in substance use disorders, with hospital care related to these issues dropping by 47% during treatment.
One of the study's authors, Professor Mark Taylor, indicated that the findings were consistent with previous research linking GLP-1 medications to reduced alcohol use disorder, which can influence mood and anxiety. Despite the strong associations observed, the researchers acknowledged that the nature of the study, being registry-based, does not allow for definitive conclusions about the mechanisms at play. Factors such as improved body image from weight loss and enhanced glycemic control may contribute to these mental health benefits, alongside potential neurobiological effects.
The study, published in The Lancet Psychiatry, adds robust evidence to the ongoing exploration of the relationship between physical health treatments and mental well-being, although further research is necessary to clarify these connections.